OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern Time
03 août 2023 07h30 HE
|
OpGen, Inc.
ROCKVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its second quarter...
OpGen Subsidiary Ares Genetics Successfully Maintains Key Patent under Opposition in Europe
26 juin 2023 07h30 HE
|
OpGen, Inc.
Patent EP 3 332 028 B1 granted by the European Patent Office covers the identification and use of genomic variants for the diagnosis of antibiotic resistant bacteria.The opposition division of...
Antibiotics Global Market Report 2023: Significant Growth Potential of Cell Wall and Protein Inhibitor Drugs Bodes Well for Sector
23 mai 2023 04h18 HE
|
Research and Markets
Dublin, May 23, 2023 (GLOBE NEWSWIRE) -- The "Antibiotics: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. The global market for antibiotics was...
Healthcare Industry Veteran Jamie Condie Joins Selux Diagnostics' Board of Directors
14 févr. 2023 07h30 HE
|
Selux Diagnostics
BOSTON, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Selux Diagnostics, a biotech startup in Boston whose mission is to combat superbug infections and antimicrobial resistance (AMR), announced today that...
FDA Clears 'Selux NGP System' for Rapid Antibiotic Susceptibility Testing
19 janv. 2023 07h00 HE
|
Selux Diagnostics
BOSTON, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Selux Diagnostics, a biotech startup in Boston whose mission is to combat superbug infections and antimicrobial resistance (AMR), announced it has received...
Global Antibiotic Resistance Market Research Report 2023: The Changing Road to New Antibiotics & Technologies with 5 Year Forecasts
13 janv. 2023 05h03 HE
|
Research and Markets
Dublin, Jan. 13, 2023 (GLOBE NEWSWIRE) -- The "Antibiotic Resistance Markets - Therapeutics by Pathogen and Therapy Type. With Situation Analysis, Executive & Investor Guides &...
Global Antibiotic Resistance Market Report 2022: New Technologies and New Drugs are Under Development to Capture this Growing Market
14 avr. 2022 04h08 HE
|
Research and Markets
Dublin, April 14, 2022 (GLOBE NEWSWIRE) -- The "Antibiotic Resistance Markets - Therapeutics by Pathogen and Therapy Type. With Situation Analysis, Executive & Investor Guides &...
Global Antibiotic Resistance Markets Report 2021: Therapeutic Technology Development Opportunities by Pathogen and Therapy Type 2020-2024
31 août 2021 05h53 HE
|
Research and Markets
Dublin, Aug. 31, 2021 (GLOBE NEWSWIRE) -- The "Antibiotic Resistance Markets - Therapeutics by Pathogen and Therapy Type 2020 to 2024" report has been added to ResearchAndMarkets.com's offering. ...
Summit Therapeutics Announces Preclinical Candidate and Associated CARB-X Funding Support for the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae, a CDC Urgent Threat and WHO Critical Priority
18 mai 2021 07h00 HE
|
Summit Therapeutics Inc.
Cambridge, MA, May 18, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) announced today that it has selected a new preclinical candidate, SMT026738 (“SMT-738”), for development in the fight against...
Entasis Therapeutics Announces Sulbactam-Durlobactam Expanded Access Program for Patients in the U.S.
26 janv. 2021 08h00 HE
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...